Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candesartan cilexetil + amlodipine besylate (Shinpoong Pharma)
- Development stage
- Phase 4
- Lead developer
- Shinpoong Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SPC3001, marketed under the brand name Candeam, is a fixed-dose combination (FDC) antihypertensive therapy developed by Shin Poong Pharmaceutical. It combines candesartan cilexetil, an angiotensin II receptor blocker (ARB), with amlodipine besylate, a dihydropyridine calcium channel blocker (CCB). Candesartan cilexetil is a prodrug that is hydrolyzed to its active form, candesartan, which selectively antagonizes the angiotensin II type 1 (AT1) receptor, thereby inhibiting vasoconstriction and aldosterone secretion. Amlodipine besylate inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to systemic vasodilation. This combination provides synergistic blood pressure reduction and was approved in South Korea in 2016. In clinical development, SPC3001 has served as a dual-therapy comparator in Phase 2 trials for Shin Poong's triple fixed-dose combination, SPC1001 (candesartan/amlodipine/indapamide).
- Brand names
- Candeam
- Other names
- candesartan cilexetil + amlodipine besylatecandesartan + amlodipine
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on candesartan cilexetil + amlodipine besylate (Shinpoong Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candesartan cilexetil + amlodipine besylate (Shinpoong Pharma).